Radar · Industry landscape · the United States
Genomics and Precision Medicine Industry Landscape of the United States
1,136 Genomics and Precision Medicine companies in the United States, in one picture: who is hiring, who is raising money, who founded them, where they are based, what the news is about, which skills employers want and where the research is going. Updated September 2026.
1,136companies tracked
$59Bdisclosed funding
124hiring right now
1,523events · 24 months
163,423news articles · 12 months
Who leads Genomics and Precision Medicine in the United States
Shows the 1,136 tracked companies, highlighting which firms are currently hiring, which have disclosed funding, and which are noted as best funded, giving a snapshot of activity across the sector.
open roles
Hiring now
ranked by live open roles
- 01
Natera11last posted Jun 2026
- 02
Guardant Health11last posted Aug 2026
- 03
Alamar Biosciences11last posted Jul 2026
- 04
Caris Life Sciences11last posted Jun 2026
- 05
Myriad Genetics11last posted Jun 2026
- 06
Twist Bioscience10last posted Jun 2026
- 07
BillionToOne10last posted Jun 2026
- 08
Neogen9last posted Jun 2026
124 companies hiring · 1 posted in the last 30 days
disclosed funding
Most funded
disclosed totals, all rounds
- 01
Invitae$2.5BPost IPO · Apr 2021
- 02
GRAIL$2.3BPost IPO · Oct 2025
- 03Amyris$2.2BPost IPO · Dec 2022
- 04
- 05
Freenome Health$1.4BSeries E · Feb 2024
- 06
PacBio$1.3BPost IPO · Feb 2021
- 07
- 08
Eikon$1.2BSeries D · Feb 2025
666 companies with disclosed rounds · $59B total
revenue
Revenue leaders
official filings first, else latest snapshot
- 01
- 02
- 03
- 04
NeoGenomics$186.7MFY2024 filing
- 05
Veracyte$139.1MFY2022 filing
- 06
- 07
- 08
Sema4$102.3MFY2023 filing
43 companies with a revenue figure
headcount
Largest teams
ranked by tracked headcount
- 01
- 02
- 03
- 04
- 05
- 06
Ginkgo Bioworks1,218tracked employees
- 07
- 08
150 companies with headcount data
share of events
Share of voice
share of all tracked sector news events, 24 months
- 01
23andMe9.3%216 tracked events
- 02
GeneDx3.2%74 tracked events
- 03
- 04
- 05
- 06
- 07
Seismic2.6%61 tracked events
- 08
2,334 tracked events across 193 companies
web reach
Most-used apps
the sites in this sector the web visits most
- 01
DioGenixtop 50khugedomains.com
- 02
GENOME LINKtop 100kgenomelink.io
- 03
Family Tree DNAtop 100kfamilytreedna.com
- 04
- 05
- 06
- 07
Genova Diagnosticstop 500kgdx.net
- 08
SelfDecodetop 1Mselfdecode.com
244 companies here run a site with a measured audience · 16 of them sit inside the web’s top million
articles
In the news
Prism news coverage, last 12 months
- 01
- 02
- 03
- 04
- 05
Intellia Therapeutics199articles in the window
- 06
- 07
Regenxbio176articles in the window
- 08
256 of these companies drew sector coverage in the window
Radar
See all 1,136 Genomics and Precision Medicine companies in the United States
Filter by funding, headcount, hiring and location, and export the list.
How the Genomics and Precision Medicine ecosystem in the United States grew, 2016–2025
Lists the number of companies founded each year from 2016 to 2025, noting the highest count of 83 in 2016 and the lowest of 5 in 2025.
Companies founded / year
new Genomics and Precision Medicine companies in the United States
20162025
peak 83 in 2016
Companies raising / year
with a disclosed round that year
20162025
peak 155 in 2021
Disclosed funding / year
sum of disclosed rounds (USD)
20162025
peak $9.8B in 2021
Where Genomics and Precision Medicine companies in the United States are based
Ranks U.S. cities by the number of sector companies located there, with San Diego leading at 84 firms followed by Cambridge, San Francisco, New York City, and Boston.
Hub 01
San Diego
84 Genomics and Precision Medicine companies
23% of the Genomics and Precision Medicine companies across these hubs
84companies
$4.5Bdisclosed funding
11hiring now
Hub 02
Cambridge
67 Genomics and Precision Medicine companies
19% of the Genomics and Precision Medicine companies across these hubs
67companies
$6.4Bdisclosed funding
13hiring now
Hub 03
San Francisco
61 Genomics and Precision Medicine companies
17% of the Genomics and Precision Medicine companies across these hubs
61companies
$5.8Bdisclosed funding
14hiring now
Hub 04
New York City
48 Genomics and Precision Medicine companies
13% of the Genomics and Precision Medicine companies across these hubs
48companies
$949.8Mdisclosed funding
2hiring now
Hub 05
Boston
36 Genomics and Precision Medicine companies
10% of the Genomics and Precision Medicine companies across these hubs
36companies
$1.9Bdisclosed funding
5hiring now
Hub 06
Seattle
27 Genomics and Precision Medicine companies
8% of the Genomics and Precision Medicine companies across these hubs
27companies
$1.5Bdisclosed funding
3hiring now
Hub 07
Rockville
19 Genomics and Precision Medicine companies
5% of the Genomics and Precision Medicine companies across these hubs
19companies
$334.8Mdisclosed funding
1hiring now
generated artwork
Hub 08
Berkeley
16 Genomics and Precision Medicine companies
4% of the Genomics and Precision Medicine companies across these hubs
16companies
$1.3Bdisclosed funding
2hiring now
generated artwork
The Genomics and Precision Medicine market map of the United States: what these companies actually do
Breaks down the main product categories these firms develop and the revenue models they use, such as subscription, fee‑for‑service, and physical commerce.
- Life Sciences1,101 companies · $57.5B raised · 120 hiring
- Enterprise Tech1,024 companies · $53.1B raised · 117 hiring
- Deep Tech821 companies · $43.7B raised · 98 hiring
- In Vitro Diagnostics314 companies · $15.2B raised · 27 hiring
- Healthtech273 companies · $12.6B raised · 30 hiring
- Enterprise Software261 companies · $11.2B raised · 21 hiring
- Biopharmaceuticals142 companies · $13B raised · 20 hiring
- Proteomics in Drug Discovery115 companies · $6.8B raised · 13 hiring
- Consumer Digital110 companies · $5.7B raised · 8 hiring
- SaaS67 companies · $4B raised · 8 hiring
- Healthtech SaaS45 companies · $3.7B raised · 7 hiring
- Life Sciences Analytics27 companies · $981M raised · 3 hiring
Monetization
How Genomics and Precision Medicine companies make money
How many companies earn revenue each way. Plenty use more than one model, so the counts add up to more than the sector.
Subscription586
Fee-For-Service297
Physical Commerce272
E-Commerce - Product136
Commission on Transaction17
Advertising7
E-Commerce - Service3
Sponsorship1
Funding, M&A and the deals moving Genomics and Precision Medicine in the United States
Counts 1,523 corporate events over the past two years, detailing types like earnings releases, key‑person announcements, funding rounds, mergers and acquisitions, and IPOs.
Earnings 390Leadership 261Funding 225M&A 142IPO 117Lawsuit 76Announcement 74Regulatory 45Assets 42Product 35
- FundingAureka Biotechnologies , a biotechnology company, has raised USD 35 million in a Series A+ round led by HongShan, with participation from Matrix Partners and BioTrack Capital. Existing backers, including 5Y Capital, Qiming Venture Partners, and NRL Capital, also joined the round.2026-04-28
- IPOIntellia Therapeutics, Inc. (Nasdaq: NTLA ), ... announced that it has commenced an underwritten public offering of $150 million of shares of its common stock.2026-04-27
- IPOAlamar Biosciences, Inc. (Alamar), a leader in precision proteomics dedicated to advancing the early detection of disease, has announced the pricing of its upsized initial public offering of 11,250,000 shares of its common stock at a public offering price of US$17 per share.2026-04-20
- FundingSolid Biosciences ... bringing in $240 million from a private placement.2026-04-08
- IPOGenerate Biomedicines had issued 25,000,000 shares in its public offering on February 27th. The total size of the offering was $400,000,000 based on an initial share price of $16.00.2026-04-01
- IPOEikon Therapeutics, which made its Nasdaq debut on Feb. 5 with a $381 million raise, designs assets by 'integrating AI capabilities and advanced automation' into its workflow to track how proteins move inside cells, according to its website.2026-04-01
- FundingUnnatural Products has now raised a total of $83.0M in total equity funding and is backed by argenx, Artis Ventures, Droia Ventures, First Spark Ventures, Merck Global Health Innovation Fund, and The Venture Collective.2026-03-23
- FundingEarlier this month, Blackstone also led a $100m private credit facility for genomic testing firm GeneDx.2026-03-19
- M&ANeoGenomics said in its most recent Form 10-K filed with the SEC that it paid $8.5 million for New Jersey-based clinical lab Pathline.2026-03-06
- M&AZoetis Inc., a leading animal health company headquartered in Parsippany, announced that it has entered into a definitive agreement with Neogen Corporation to acquire its animal genomics business for $160 million, subject to customary closing adjustments.2026-03-03
Mergers and acquisitions
Deals from the last 24 months where a Genomics and Precision Medicine company in the United States was the buyer or the one bought, newest first. “Undisclosed” means the price was never published — not that the deal was worth nothing.
| Acquirer | Target | Deal value | Status | Date |
|---|---|---|---|---|
| $256M | Announced | 2026-05-19 | ||
| $8.5M | Completed | 2026-03-06 | ||
| undisclosed | Announced | 2026-03-06 | ||
| $160M | Announced | 2026-03-03 | ||
| undisclosed | Completed | 2026-03-02 | ||
| $149M | Completed | 2026-02-23 |
Who is listing, hiring leaders, launching and winning work
Details specific event types including IPO filings, leadership changes, product launches, and contract wins, providing deeper insight into notable corporate activities.
IPO pipeline
46 companies listed or filing · last 24 months
Generate BiomedicinesIPO · NASDAQ · GENB · 6 reportsApr 2026
Candel TherapeuticsIPO · Nasdaq · CADL · 5 reportsFeb 2026
Leadership moves
57 tracked people moves · last 12 months
Singular GenomicsJohn Stark · Appointment → Chief Executive OfficerMay 2026
Delfi DiagnosticsCharles Newton · Appointment → Board MemberMay 2026
Prime MedicineSvetlana Makhni · Appointment → Chief Financial OfficerApr 2026
Frontier MedicinesDavid R. Epstein · Appointment → Member of the Board of DirectorsApr 2026
Product launches
tracked launches · last 12 months
Lantern PharmawithZeta.ai (AI platform for rare cancer drug discovery)Apr 2026
Contract wins
19 customer wins · last 24 months
Sequenomwon invitrogenFeb 2025
Transgenomicwon Geron Corp.Feb 2025
Codexiswon matrix laboratoriesFeb 2025
Transposagen Biopharmaceuticalswon trans genicFeb 2025
Workforce actions
19 companies cutting roles · last 24 months
Tessera Therapeutics~90 roles reported · budget constraintsApr 2026
Voyager Therapeutics~30 roles reportedDec 2025
Metagenomi~25% of workforce reported · cash runway extensionNov 2025
Seres Therapeutics~25% of workforce reported · cost reductionSep 2025
Poseida Therapeutics~52 roles reported · post-acquisitionSep 2025
Blue Rock Therapeutics~50 roles reported · streamline pipelineSep 2025
Regulatory & litigation
43 regulatory events · 34 tracked suits · 24 months
Precision BioSciencesapproved grant of inducement award — NasdaqDec 2025
Opus Geneticsapproved small-molecule therapyDec 2025
- Investors purchasing REGENXBIO Inc. common shares v regenxbiosecurities law violationsApr 2026
- natera v archerdx, invitaepatent infringement · VerdictApr 2026
Earnings pulse
companies reporting results · last 24 months
52 companies reporting459 company-quarters trackedbeat 114miss 54in line 7
Half of these companies grew revenue faster than +19.3%, half slower.
Who is building Genomics and Precision Medicine in the United States
Profiles 1,022 founders and CEOs across 675 companies, noting frequent alma maters like MIT and Harvard and common prior employers such as McKinsey and Microsoft.
Founders and chief executives12 of 1,022, from the best-funded companies on this page
Foundation, Co-Founder Freenome & Oncolinx, ex-Foundation Medicine, Syros Pharmaceuticals, Morgan Stanley. Dartmouth College BA 2015
Wave Life Sciences, Ginkgo Bioworks, Ex- Illumina, Tickets. UC San Diego BA 1990, University of California…
Scientific Partner-TCG Labs-Soleil
Ex-Passport Capital, Andor Capital Management, Ardsley partners. Yale University BS 1996
Liquidia, Bull City Select Investments, ex-Pluristem Therapeutics, United Therapeutics, Amgen, Cusham Darby & Cushman. Duke University BA 1984…
Ginkgo Bioworks, ex-Massachusetts Institute Of Technology, Massachusetts Institute of Technology, 2008
Ex-3SBio · Peking Union Medical College MSc 1988, Dalhousie University PhD 1993
repeat founder
Co-Founder Groupon, Lightbank, MediaBank, ex-Founder Echo Global Logistics. University of Michigan 1991, University of Michigan Law School JD 1994
Ex-Kaleido Biosciences, Boeing. Truman State University BS 2009, Washington University School of Medicine in St. Louis PhD 2015
Where the founders studied
alma mater on record for 276 of 1,022 founders
Massachusetts Institute of Technology55
Harvard University46
Stanford University40
University of California (Berkeley)28
Harvard Business School20
University of Pennsylvania17
Cornell University16
Yale University13
Where they worked before
a previous employer on record for 21 of 1,022 founders
McKinsey5
Microsoft5
Google3
Amazon2
Intel2
Bain2
Boston Consulting Group1
Morgan Stanley1
Founders flagged as repeat founders
of 950 founders with a profile on this page
16
carry a repeat-founder flag
- flagged as repeat founders16
- no repeat-founder flag934
Women and men among the founders
first names matched for 913 of 1,022 founders
15%
of matched founders are women
- women138
- men775
Inferred from first names, using 119 million people who state their own gender: a first name counts only where at least 20 of them share it and at least 90% of those share the same gender. The other 109 founders go in neither column.
Radar
Look up the people behind Genomics and Precision Medicine companies in the United States
Search founders, executives and operators by company, role and location.
Who funds Genomics and Precision Medicine in the United States
Summarizes 1,838 funding rounds since 2016 from 1,330 investors, with a typical round size of $3.2 million.
| Investor · most active investors since 2016 | Rounds | Led | Latest |
|---|---|---|---|
| HHS | 367 | — | Sep 2025 |
| National Science Foundation | 38 | — | May 2025 |
| Y Combinator | 36 | 16 | Mar 2025 |
| Arch Venture Partners | 35 | 13 | Nov 2025 |
| RA Capital Management | 34 | 10 | Mar 2026 |
| Casdin Capital | 32 | 12 | Apr 2023 |
| Perceptive Advisors | 28 | 6 | Mar 2026 |
| Alexandria | 27 | 1 | Jan 2026 |
| Orbimed | 25 | 8 | Nov 2025 |
| T. Rowe Price | 24 | 8 | Jan 2026 |
Stage mix · rounds since 2016
Seed & Angel305
Series A–B525
Series C+ / PE210
Grants, debt & other798
The typical round is $3.2M — half were bigger, half smaller.
The biggest Genomics and Precision Medicine funding rounds in the United States
Lists the ten largest disclosed funding rounds, with the biggest being GRAIL’s $1.2 billion Series B round.
Venture round sizes · 2023–2025
<$1M24
$1–10M69
$10–50M62
$50–250M32
>$250M4
191 venture rounds with a disclosed amount in the window.
Fresh cheques · last 6 months
Series A$97MMay 2026
Series C$59.7MMay 2026
Grant (prize money)$23kMay 2026
Series BundisclosedMay 2026
Series A$35MApr 2026
Series A$5MApr 2026
Series BundisclosedApr 2026
What the news says about Genomics and Precision Medicine in the United States
Counts 163,423 news articles in the last year and identifies the most covered topics, including patent law, oncology advances, rare‑disease therapies, and gene‑editing technologies.
News volume
Genomics and Precision Medicine coverage across United States · articles per quarter
2021Q22026Q1
peak 162,633 in 2025Q1 · 163,423 articles in the last 12 tracked months
Tone of coverage
share of articles by dominant sentiment (positive / neutral / negative)
202120232025
Positive-tone share moved 85% → 83%, negative 14% → 15% across 2021–2025.
What the coverage is about
The subjects that dominate Genomics and Precision Medicine news in United States. The arrow shows whether each one is being written about more or less than a year ago.
- Patent law & innovation protection116,460▼-99%
- Oncology and targeted therapy advancements28,440▼-27%
- Rare disease therapies and orphan drugs22,835▼-27%
- Gene therapy and crispr technologies19,287▼-26%
- Drug pricing and reimbursement strategies19,104▲+38%
- Covid-19 vaccine development and efficacy trials17,432▲+58%
- Vaccine research and production methods14,227▼-20%
- Generic drug development and market trends13,278▲+21%
- Biotechnology innovations in medicine11,988▲+16%
- Pharmaceutical marketing and sales strategies11,170▲+65%
Most-covered companies · last 12 months
- 394
- 243
- 242
- 217
- 199
- 197
- 176
- 170
- 165
- 155
256 Genomics and Precision Medicine companies here were named in the news over this period.
Prism
Watch Genomics and Precision Medicine coverage in United States as it happens
Prism follows these subjects story by story — which companies are named, what is said about them and how the tone moves.
Momentum
The words getting louder — and quieter
Which terms are showing up in more stories than a year ago, and which are fading. The percentage is the change in how many articles mention them.
copyright enforcement+70%ai copyright issues+94%copyright remedies+77%angel investors+128%copyright exceptions+89%copyright fair use+84%copyright assignment+111%ai liability+154%copyright duration+173%vaccine trials+64%
patent prosecution-99%patent claims-99%patent examination-99%litigation defenses-99%cell-based therapies-42%
The pressures the press keeps returning to
Three recurring angles in United States Genomics and Precision Medicine coverage, and whether each is getting more attention year on year (through 2025).
Regulatory Risk ▲ rising
140,861 articles touch this dimension · 49.2% critical tone
20212025
signals: stem cell banking, generic drug approval, vaccine trials
Funding Momentum ▲ rising
73,915 articles touch this dimension · 53.0% critical tone
20212025
signals: angel investors, therapeutic development funding, vaccine candidates
Growth ▲ rising
92,030 articles touch this dimension · 44.6% critical tone
20212025
signals: earnings report, urban population growth, population growth trajectories
Genomics and Precision Medicine jobs in the United States: who is hiring and what they ask for
Reports 1,964 job postings from 144 employers over 12 months, highlighting common skill requirements and a median advertised salary of $143 k per year.
1,964postings · last 12 months
3,104postings tracked overall
144employers advertising
$143kmedian advertised salary/yr (n=255)
Demand
The Skills Employers Ask For
What Genomics and Precision Medicine employers in the United States put in their job ads. The bar is how many postings ask for it; the arrow shows whether demand grew or shrank against the year before.
- excel56▲
- python45▲
- sql29▲
- aws26▲
- word25▲
- salesforce21▲
- molecular profiling20▲
- oncology guidelines20▲
- react20▲
- resistance mechanisms20▲
What level are these roles?
Entry4
Intern31
Senior412
Lead239
Manager659
What they pay, by level
- Manager$155k/yr (n=91)
- Senior$139k/yr (n=43)
Most advertised titles
- 152
- 120
- 81
- 58
- 18
- 18
What Genomics and Precision Medicine research in the United States is working on
Aggregates 13,110 U.S. academic papers, categorizing them into identified problems, cautions, and opportunities, with opportunities comprising the largest share.
How this field talks about itself
United States-affiliated Genomics and Precision Medicine papers (gold) against all published research (grey)
Breakthrough38.4% · 26.2%1.5×
Promising26.6% · 36.9%0.7×
Descriptive17.0% · 17.8%≈ par
Problem-identifying10.4% · 9.7%≈ par
Cautionary4.0% · 4.4%≈ par
Comparative2.0% · 4.1%0.5×
United States-affiliated Genomics and Precision Medicine literature runs 1.5× more “breakthrough” than science at large (38.4% vs 26.2% baseline).
How the work is done
Empirical38.6%
Methods-led34.1%
Reviews23.6%
Position pieces3.0%
Theoretical0.7%
How the research reads
92% positive · 5% neutral · 3% negative, across 13,110 papers.
The institutions doing the work · United States
- 424k
- 397k
- 309k
- 202k
- 184k
- 173k
ranked by how often their work is cited
Leading researchers · United States-affiliated work
Koichiro Tamura · Glen Stecher · Michael I. Love · Wolfgang Huber · Simon Anders · Sudhir Kumar · Douglas Hanahan · Robert A. Weinberg
The most-cited breakthroughs
- Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 · 97k cites
- MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets · 45k cites
- MEGA5: Molecular Evolutionary Genetics Analysis Using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods · 40k cites
- MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms · 38k cites
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data · 29k cites
Common problems researchers identify1,536 papers · 7 recurring themes
Problems · theme 01
Translating Biomarkers to Clinical Trials
280 papers · 18.2% of this block
▲ +46% share2022→2025 share of research on this subject
Researchers highlight gaps in moving metabolic and disease biomarkers from discovery to patient trials.
Clinical trial · MEDLINE · Biomarker · Disease
“Evolving Paradigms in Chronic Limb-threatening Ischemia: A Systematic Review of Current and Emerging Diagnostic and Therapeutic Approaches”
280 of these papers raise it as a problem
Problems · theme 02
Tumor Microenvironment and Immunotherapy Gaps
269 papers · 17.5% of this block
▼ -4% share2022→2025 share of research on this subject
Papers point out unresolved challenges in targeting immune checkpoints and metabolic pathways in cancer.
Cancer · Tumor microenvironment · Breast cancer · Immunotherapy
“Metabolic reprogramming and cancer progression”
269 of these papers raise it as a problem
Problems · theme 03
Interpretation of Genetic Variants
262 papers · 17.1% of this block
▼ -23% share2022→2025 share of research on this subject
Authors flag difficulties in classifying and reporting gene‑level findings for disease risk.
Gene · Genome · Gene expression · Genetic testing
“Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test result”
262 of these papers raise it as a problem
Problems · theme 04
Inflammation‑Driven Disease Mechanisms
262 papers · 17.1% of this block
▼ -13% share2022→2025 share of research on this subject
Studies emphasize incomplete understanding of immune and metabolic links to neuro‑ and cardiovascular disorders.
Disease · Inflammation · Pathogenesis · Immune system
“Parkinson’s disease: etiopathogenesis and treatment”
262 of these papers raise it as a problem
Problems · theme 05
Computational and Synthetic Biology Limits
184 papers · 12.0% of this block
▼ -6% share2022→2025 share of research on this subject
Works note methodological bottlenecks in applying bio‑informatics and synthetic tools to clinical contexts.
Computational biology · Synthetic biology · Extracellular vesicles · Regenerative medicine
“Clinical metagenomics”
184 of these papers raise it as a problem
Problems · theme 06
Metabolic Disease Complexity
173 papers · 11.3% of this block
▼ -15% share2022→2025 share of research on this subject
Researchers discuss intertwined obesity, insulin resistance, and inflammatory pathways that hinder treatment progress.
Diabetes mellitus · Disease · Obesity · Insulin resistance
“Inflammatory mechanisms linking obesity and metabolic disease”
173 of these papers raise it as a problem
Problems · theme 07
Microbiome Knowledge Gaps
106 papers · 6.9% of this block
▲ +30% share2022→2025 share of research on this subject
Papers identify unknowns in gut flora dynamics and therapeutic modulation across health and disease.
Microbiome · Gut microbiome · Human microbiome · Gut flora
“Microbiota in health and diseases”
106 of these papers raise it as a problem
Cautions511 papers · 7 recurring themes
Cautions · theme 01
Cautious Optimism in Cancer Immunotherapy
98 papers · 19.2% of this block
▼ -3% share2022→2025 share of research on this subject
Authors urge careful validation of combination strategies and genomic biomarkers before clinical rollout.
Cancer · Breast cancer · Transcriptome · Tumor microenvironment
“[Strategic Combination Approaches in Cancer Immunotherapy].”
98 of these papers raise it as a problem
Cautions · theme 02
Drug Development and Clinical Trial Risks
94 papers · 18.4% of this block
▲ +43% share2022→2025 share of research on this subject
Studies caution about translational hurdles and safety uncertainties for emerging therapeutics.
Drug · Drug discovery · Clinical trial · Disease
“The therapeutic potential of resveratrol: a review of clinical trials”
94 of these papers raise it as a problem
Cautions · theme 03
Epigenetic and Protein Structure Uncertainties
87 papers · 17.0% of this block
▼ -27% share2022→2025 share of research on this subject
Researchers warn that epigenetic markers and protein dynamics may not yet be reliable for diagnostics.
DNA methylation · Antibody · Protein structure · Epigenetics
“Characterizing the Conformational Dynamics of an Intrinsically Disordered Localization Sequence”
87 of these papers raise it as a problem
Cautions · theme 04
Genome Editing in Non‑Human Systems
72 papers · 14.1% of this block
▼ -29% share2022→2025 share of research on this subject
Papers caution against over‑extrapolating plant genome‑selection results to human medicine.
Gene · Genetic testing · Genome editing · Genome
“Genomic Selection for Crop Improvement”
72 of these papers raise it as a problem
Cautions · theme 05
Diabetes Therapeutic Evidence Gaps
71 papers · 13.9% of this block
▼ -15% share2022→2025 share of research on this subject
Authors highlight limited long‑term data and variable outcomes for newer diabetes interventions.
Diabetes mellitus · Type 2 diabetes · Disease · MEDLINE
“Dose-dependent effects of SGLT2 inhibitors on circadian blood pressure in hypertensive patients with diabetes: A systematic review and Bayes”
71 of these papers raise it as a problem
Cautions · theme 06
Sequencing Bias and Benchmarking Issues
59 papers · 11.5% of this block
▼ -3% share2022→2025 share of research on this subject
Works stress the need for robust standards to address systematic errors in genomic data.
DNA sequencing · Genome · Computational biology · Benchmark
“Characterizing and measuring bias in sequence data”
59 of these papers raise it as a problem
Cautions · theme 07
Microbiome‑Cancer Association Uncertainty
30 papers · 5.9% of this block
▲ +31% share2022→2025 share of research on this subject
Studies advise prudence when linking gut microbial changes to colorectal cancer risk.
Microbiome · Gut flora · Gut microbiome · Metagenomics
“Long-term impacts of antibiotic exposure on the human intestinal microbiota”
30 of these papers raise it as a problem
Opportunities8,195 papers · 7 recurring themes
Opportunities · theme 01
Targeting Inflammation in Metabolic Disease
1,108 papers · 18.5% of this block
▼ -13% share2022→2025 share of research on this subject
Research points to promising therapeutic avenues that modulate immune pathways in diabetes and related disorders.
Disease · Inflammation · Diabetes mellitus · Immune system
“Mitochondrial Dysfunction in Diabetes: From Molecular Mechanisms to Functional Significance and Therapeutic Opportunities”
Opportunities · theme 02
Genomic Insights for Disease and Drug Targets
1,039 papers · 17.3% of this block
▼ -23% share2022→2025 share of research on this subject
Large‑scale association studies reveal tissue‑specific genes that can guide precision therapies.
Genome · Gene · Genomics · Genome-wide association study
“Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types”
Opportunities · theme 03
Multi‑Omic Computational Workflows
951 papers · 15.8% of this block
▼ -6% share2022→2025 share of research on this subject
Advances in proteomics and bio‑informatics enable integrated models of protein‑nucleic acid interactions.
Proteomics · Proteome · Computational biology · Workflow
“Metabolic Reconstruction for Metagenomic Data and Its Application to the Human Microbiome \n”
Opportunities · theme 04
Novel Antimicrobial Discovery Platforms
887 papers · 14.8% of this block
▲ +38% share2022→2025 share of research on this subject
Innovative screening and microphysiological systems accelerate identification of new antibiotics and therapeutics.
Antimicrobial · Epitope · Drug discovery · Antibiotics
“Bioactive Phytochemicals in Experimental Models of Multiple Sclerosis: Mechanisms, Efficacy, and Translational Potential”
Opportunities · theme 05
Cancer Biomarkers and Immunotherapy Advances
863 papers · 14.4% of this block
▼ -3% share2022→2025 share of research on this subject
Emerging microRNA signatures and modeling tools expand diagnostic and treatment options for solid tumors.
Cancer · Breast cancer · Immunotherapy · Colorectal cancer
“MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer”
Opportunities · theme 06
CRISPR‑Based Genome Editing Expansion
667 papers · 11.1% of this block
▲ +11% share2022→2025 share of research on this subject
New CRISPR tools broaden capabilities for multiplexed editing and RNA targeting in therapeutic contexts.
CRISPR · Genome editing · Cas9 · Gene
“Multiplex Genome Engineering Using CRISPR/Cas Systems”
Opportunities · theme 07
Spatial Transcriptomics for Cellular Profiling
485 papers · 8.1% of this block
▼ -21% share2022→2025 share of research on this subject
Techniques reconstruct coherent gene expression maps, enhancing disease modeling and target discovery.
Transcriptome · Transcription factor · Gene · Gene expression
“Reconstructing biologically coherent cellular profiles from imaging-based spatial transcriptomics”
Which of these themes are growing fastest
Tracks how the share of different research themes has changed worldwide between 2022 and 2025.
Problems
how much more (or less) of the world’s research on this subject each theme took up, 2022→2025
gaining sharelosing share
Translating Biomarkers to Clinical Trials▲+46%
Microbiome Knowledge Gaps▲+30%
Tumor Microenvironment and Immunotherapy Gaps▼-4%
Computational and Synthetic Biology Limits▼-6%
Inflammation‑Driven Disease Mechanisms▼-13%
Metabolic Disease Complexity▼-15%
Interpretation of Genetic Variants▼-23%
Cautions
how much more (or less) of the world’s research on this subject each theme took up, 2022→2025
gaining sharelosing share
Drug Development and Clinical Trial Risks▲+43%
Microbiome‑Cancer Association Uncertainty▲+31%
Cautious Optimism in Cancer Immunotherapy▼-3%
Sequencing Bias and Benchmarking Issues▼-3%
Diabetes Therapeutic Evidence Gaps▼-15%
Epigenetic and Protein Structure Uncertainties▼-27%
Genome Editing in Non‑Human Systems▼-29%
Opportunities
how much more (or less) of the world’s research on this subject each theme took up, 2022→2025
gaining sharelosing share
Novel Antimicrobial Discovery Platforms▲+38%
CRISPR‑Based Genome Editing Expansion▲+11%
Cancer Biomarkers and Immunotherapy Advances▼-3%
Multi‑Omic Computational Workflows▼-6%
Targeting Inflammation in Metabolic Disease▼-13%
Spatial Transcriptomics for Cellular Profiling▼-21%
Genomic Insights for Disease and Drug Targets▼-23%
Prism
Go deeper on Genomics and Precision Medicine research and innovation
Research themes, patent activity and the companies commercialising them, in one place.
Keep going
Track Genomics and Precision Medicine in the United States beyond this page
Radar finds and filters the companies. Prism watches what is being said about them.
About this data: built from Fliar's company, founder, funding, hiring, jobs, news and research trackers, covering the United States. Counts are of companies we track, not of every company that exists. Updated September 2026.
Contact details
Reach this founder through Fliar Radar
Direct contact details for the people on this page are held in Fliar Radar, behind its own access controls.